Search

Your search keyword '"Tomii, Keisuke"' showing total 8 results
Start Over Author "Tomii, Keisuke" Language undetermined
8 results on '"Tomii, Keisuke"'

2. Additional file 2 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Author

Hosoya, Kazutaka, Fujimoto, Daichi, Morimoto, Takeshi, Kumagai, Toru, Tamiya, Akihiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Ishida, Tadashi, Matsumoto, Hirotaka, Hirano, Katsuya, Kominami, Ryota, Tomii, Keisuke, Suzuki, Hidekazu, Hirashima, Tomonori, Tanaka, Satoshi, Uchida, Junji, Morita, Mitsunori, Kanazu, Masaki, Mori, Masahide, Nagata, Kenji, Fukuda, Ikue, and Tamiya, Motohiro

Abstract

Additional file 2 Supplementary Fig. 1. Progression-free survival (A) and overall survival (B) in all patients who received first-line pembrolizumab. Generated using JMP software (version 14; SAS Institute, Cary, NC, USA). Supplementary Fig. 2. Flow chart of the study patients. Supplementary Fig. 3. Progression-free survival (PFS) in patients with response, stratified by sex (A), smoking history (B), histology (C), stage (D), and presence of pleural effusion or dissemination (E), brain metastasis (F), adrenal grand metastasis (G), liver metastasis (H), early immune-related adverse events (irAEs) (I). Generated using JMP software (version 14; SAS Institute, Cary, NC, USA). Supplementary Fig. 4. Pie-chart summarizing the organs with progressive lesions. Patients with progression in one organ (blue), 2 organs (orange), or 3 or more organs (grey). Supplementary Fig. 5. The 2nd progression-free survival of patients who developed acquired resistance, received local ablative therapy and pembrolizumab therapy beyond 1st PD. Generated using JMP software (version 14; SAS Institute, Cary, NC, USA).

Published
2021
Full Text
View/download PDF

3. Additional file 1 of Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study

Author

Niwamoto, Takafumi, Handa, Tomohiro, Murase, Yuko, Nakatsuka, Yoshinari, Tanizawa, Kiminobu, Taguchi, Yoshio, Tomioka, Hiromi, Tomii, Keisuke, Kita, Hideo, Uyama, Michihiro, Tsuchiya, Michiko, Emura, Masahito, Kawamura, Tetsuji, Arai, Naoki, Arita, Machiko, Uno, Kazuko, Yoshizawa, Akihiko, Uozumi, Ryuji, Yamaguchi, Izumi, Matsuda, Fumihiko, Chin, Kazuo, and Hirai, Toyohiro

Subjects
respiratory system, respiratory tract diseases
Abstract

Additional file 1: Table S1. Results of 48-plex measurement in the sera of IPF patients (discovery cohort) and controls and the bronchoalveolar lavage fluid of IPF patients. Measurements (median and IQR) of 48 cytokines in the discovery cohort sera (n = 100) and the control group sera (n = 32), p-values for between-group comparisons, and the measurements of BALF in the discovery cohort (n = 30).

Published
2021
Full Text
View/download PDF

4. Additional file 1 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Author

Hosoya, Kazutaka, Fujimoto, Daichi, Morimoto, Takeshi, Kumagai, Toru, Tamiya, Akihiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Ishida, Tadashi, Matsumoto, Hirotaka, Hirano, Katsuya, Kominami, Ryota, Tomii, Keisuke, Suzuki, Hidekazu, Hirashima, Tomonori, Tanaka, Satoshi, Uchida, Junji, Morita, Mitsunori, Kanazu, Masaki, Mori, Masahide, Nagata, Kenji, Fukuda, Ikue, and Tamiya, Motohiro

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2021
Full Text
View/download PDF

5. Additional file 3 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Author

Hosoya, Kazutaka, Fujimoto, Daichi, Morimoto, Takeshi, Kumagai, Toru, Tamiya, Akihiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Ishida, Tadashi, Matsumoto, Hirotaka, Hirano, Katsuya, Kominami, Ryota, Tomii, Keisuke, Suzuki, Hidekazu, Hirashima, Tomonori, Tanaka, Satoshi, Uchida, Junji, Morita, Mitsunori, Kanazu, Masaki, Mori, Masahide, Nagata, Kenji, Fukuda, Ikue, and Tamiya, Motohiro

Subjects
Data_FILES
Abstract

Additional file 3.

Published
2021
Full Text
View/download PDF

6. Additional file 1: of Prognostic significance of crazy paving ground grass opacities in non-HIV Pneumocystis jirovecii pneumonia: an observational cohort study

Author

Kumagai, Shogo, Arita, Machiko, Koyama, Takashi, Kumazawa, Takao, Inoue, Daiki, Nakagawa, Atsushi, Kaji, Yusuke, Furuta, Kenjiro, Motonari Fukui, Tomii, Keisuke, Taguchi, Yoshio, Tomioka, Hiromi, and Ishida, Tadashi

Abstract

Table S1. Univariate analysis for mortality. A univariate Cox regression analyses were employed to identify significant prognostic factors. (DOCX 15 kb)

Published
2019
Full Text
View/download PDF

7. Additional file 1: Table S1. of The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Author

Sato, Yuki, Fujimoto, Daichi, Uehara, Keiichiro, Shimizu, Ryoko, Ito, Jiro, Kogo, Mariko, Teraoka, Shunsuke, Kato, Ryoji, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Hamakawa, Hiroshi, Takahashi, Yutaka, Imai, Yukihiro, and Tomii, Keisuke

Subjects
respiratory system
Abstract

Characteristics and differences by serum CYFRA 21-1 levels in patients with advanced-stage lung adenocarcinoma. (DOCX 24 kb)

Published
2016
Full Text
View/download PDF

8. Additional file 1: Table S1. of The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Author

Sato, Yuki, Fujimoto, Daichi, Uehara, Keiichiro, Shimizu, Ryoko, Ito, Jiro, Kogo, Mariko, Teraoka, Shunsuke, Kato, Ryoji, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Hamakawa, Hiroshi, Takahashi, Yutaka, Imai, Yukihiro, and Tomii, Keisuke

Subjects
respiratory system
Abstract

Characteristics and differences by serum CYFRA 21-1 levels in patients with advanced-stage lung adenocarcinoma. (DOCX 24 kb)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results